Pioneer Investment Management Inc. Has $14.77 Million Holding in Zimmer Biomet Stake Inc (ZBH)

Pioneer Investment Management Inc. Has $14.77 Million Holding in Zimmer Biomet Stake Inc (ZBH)

Pioneer Investment Management Inc. raised its stake in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) by 60.3% during the first quarter, Holdings Channel reports. The institutional investor owned 120,968 shares of the medical equipment provider’s stock after buying an additional 45,509 shares during the period. Pioneer Investment Management Inc.’s holdings in Zimmer Biomet Holdings were worth $14,771,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in ZBH. Parkside Financial Bank & Trust raised its stake in Zimmer Biomet Holdings by 2.7% in the first quarter. Parkside Financial Bank & Trust now owns 839 shares of the medical equipment provider’s stock valued at $102,000 after buying an additional 22 shares in the last quarter. Independent Advisor Alliance acquired a new stake in Zimmer Biomet Holdings during the fourth quarter valued at about $103,000. Johnson Financial Group Inc. raised its stake in Zimmer Biomet Holdings by 17.4% in the fourth quarter. Johnson Financial Group Inc. now owns 977 shares of the medical equipment provider’s stock valued at $100,000 after buying an additional 145 shares in the last quarter. Capital Guardian Trust Co. raised its stake in Zimmer Biomet Holdings by 52.1% in the fourth quarter. Capital Guardian Trust Co. now owns 1,229 shares of the medical equipment provider’s stock valued at $127,000 after buying an additional 421 shares in the last quarter. Finally, Ledyard National Bank raised its stake in Zimmer Biomet Holdings by 9.3% in the first quarter. Ledyard National Bank now owns 1,293 shares of the medical equipment provider’s stock valued at $157,000 after buying an additional 110 shares in the last quarter. Hedge funds and other institutional investors own 86.62% of the company’s stock.

Shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) opened at 123.94 on Monday. The company’s 50-day moving average price is $119.96 and its 200-day moving average price is $114.46. The firm has a market cap of $24.99 billion, a P/E ratio of 50.73 and a beta of 1.20. Zimmer Biomet Holdings Inc has a 12 month low of $95.63 and a 12 month high of $133.21.

Zimmer Biomet Holdings (NYSE:ZBH) last issued its earnings results on Thursday, April 27th. The medical equipment provider reported $2.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.11 by $0.02. Zimmer Biomet Holdings had a net margin of 3.90% and a return on equity of 16.66%. The business had revenue of $1.98 billion for the quarter, compared to analysts’ expectations of $1.96 billion. During the same quarter in the previous year, the firm posted $2.00 EPS. The business’s revenue for the quarter was up 3.8% compared to the same quarter last year. On average, analysts predict that Zimmer Biomet Holdings Inc will post $8.54 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 28th. Shareholders of record on Friday, June 23rd will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Wednesday, June 21st. This represents a $0.96 dividend on an annualized basis and a yield of 0.77%. Zimmer Biomet Holdings’s payout ratio is 65.31%.

Several research firms have issued reports on ZBH. ValuEngine lowered Zimmer Biomet Holdings from a “buy” rating to a “hold” rating in a research note on Friday. Canaccord Genuity restated a “buy” rating on shares of Zimmer Biomet Holdings in a research note on Friday, April 28th. Needham & Company LLC restated a “strong-buy” rating and issued a $151.00 price objective on shares of Zimmer Biomet Holdings in a research note on Friday, February 17th. Goldman Sachs Group Inc began coverage on Zimmer Biomet Holdings in a research note on Tuesday, May 16th. They issued a “sell” rating and a $92.00 price objective on the stock. Finally, Wells Fargo & Co lowered Zimmer Biomet Holdings from an “outperform” rating to a “market perform” rating in a research note on Friday, April 28th. Two research analysts have rated the stock with a sell rating, five have given a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Zimmer Biomet Holdings presently has an average rating of “Buy” and an average target price of $133.82.

In other Zimmer Biomet Holdings news, VP Chad F. Phipps sold 6,200 shares of the business’s stock in a transaction on Friday, May 5th. The shares were sold at an average price of $116.76, for a total transaction of $723,912.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider David C. Dvorak sold 1,040 shares of the business’s stock in a transaction on Monday, March 20th. The shares were sold at an average price of $121.63, for a total transaction of $126,495.20. Following the sale, the insider now directly owns 294,077 shares in the company, valued at approximately $35,768,585.51. The disclosure for this sale can be found here. Insiders have sold a total of 94,571 shares of company stock worth $11,021,849 in the last three months. Insiders own 1.22% of the company’s stock.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “ZBH”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Related posts

Leave a Comment